Combined medication mode for synergistically treating human brain glioma
A technology of human glioma and drug combination, which is applied in the field of pharmacology, can solve problems such as changes in protein expression levels, and achieve a strong synergistic effect
Pending Publication Date: 2022-02-15
SOUTHEAST UNIV
View PDF0 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
It has been shown in previous studies that temozolomide also has strong anti-vascular activity and anti-tumor proliferation ability; temozolomide has good fat solubility, so it is easy to reach the target site through the blood-brain barrier, and it also has mild superimposed toxicity, anti-tumor It has a wide tumor spectrum, can be taken orally and can be quickly absorbed, is highly fat-soluble and easy to pass through the blood-brain barrier, and has high bioavailability, so it is often used as a first-line chemotherapy drug against glioma in clinical practice. In addition, Temozolomide also has a certain therapeutic effect on melanoma, lymphoma, leukemia, etc.; in clinical practice, if a single antineoplastic drug is administered to patients for a long time, gene mutations and stem cell target deletions will occur, which may lead to some important Changes in the expression levels of proteins that induce drug resistance
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment
[0042] 1. Cell culture:
[0043] Human glioma cells were cultured in DMEM medium containing 10% calf serum in an incubator at 37°C, 5% CO2, and 90% relative humidity; Remove the culture medium, digest with 0.25% trypsin, subculture in separate bottles for 2 to 3 days, and take the cells in the logarithmic growth phase for experiments;
[0044] 2. Detection of glioma cell proliferation by MTT method:
[0045] The tumor cells in the logarithmic growth phase were digested with trypsin and made into 3×10 4 100 μL of each well of the cell suspension was added to a 96-well plate, and 100 μL of different concentrations of TMZ or PPZ and combined drugs were added to each well after 24 hours. The corresponding medium was added to the solvent control group, and 3 parallel wells were set for each concentration. After incubating at 37°C for 120 h, the supernatant was discarded, and 0.5 mg·mL was added to each well - 1 100 μL of MTT solution, cultured at 37°C for 4 hours, discarded the...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more PUM
Login to view more Abstract
The invention discloses a combined medication mode for synergistically treating human brain glioma, and belongs to the technical field of pharmacology. Through the combined use of two tumor cell inhibiting drugs, i.e. Perphenazine and temozolomide are combined to treat human brain glioma cells, a model is established to quantify a combined effect. By selecting different concentrations of a stem cell inhibitor perphenazine and a human brain glioma chemotherapeutic drug temozolomide, the proliferation of U87 cells and U251 cells is inhibited by combined administration, the combination index (CI) value obtained by model quantification after the two drugs are combined for use reaches 0.3299 +/-0.002, and a strong synergistic effect is achieved; through colony formation experiment detection, the cell clone formation rate of a drug combination group is obviously lower than that of a control group and a single drug administration group, and a novel and creative drug administration mode can provide a novel drug administration strategy for treating human brain glioma.
Description
technical field [0001] The invention belongs to the technical field of pharmacology, and relates to a combined drug method with synergistic treatment of human brain glioma; specifically, it relates to the combined use of two drugs for inhibiting tumor cells, that is, the combination of perphenazine and temozolomide for the treatment of human brain glioma Tumor cells, and then establish a model to quantify the combined effect. Background technique [0002] Cancer refers to malignant tumors originating from epithelial tissue, and is the most common type of malignant tumors; generally speaking, "cancer" usually refers to all malignant tumors; cancer has abnormal cell differentiation and proliferation, and out-of-control growth. Biological characteristics such as invasiveness, invasion, and metastasis are a complex multi-factor and multi-step process. At present, cancer treatment is mainly based on surgery, radiotherapy, and systemic therapy, and systemic therapy includes chemot...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more Application Information
Patent Timeline
Login to view more Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/5415A61K31/4188A61P35/00
CPCA61K31/4188A61K31/5415A61P35/00A61K2300/00
Inventor 陈飞虹田文源邹小凤
Owner SOUTHEAST UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap